AVEYABEK Trademark

Trademark Overview


On Monday, April 20, 2020, a trademark application was filed for AVEYABEK with the United States Patent and Trademark Office. The USPTO has given the AVEYABEK trademark a serial number of 88879904. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 2, 2024. This trademark is owned by Celgene Corporation. The AVEYABEK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
aveyabek

General Information


Serial Number88879904
Word MarkAVEYABEK
Filing DateMonday, April 20, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 1, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 29, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 23, 2020NEW APPLICATION ENTERED
Wednesday, April 29, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, July 11, 2020ASSIGNED TO EXAMINER
Tuesday, July 14, 2020NON-FINAL ACTION WRITTEN
Tuesday, July 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 26, 2021FINAL REFUSAL WRITTEN
Tuesday, April 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 12, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 1, 2021PUBLISHED FOR OPPOSITION
Tuesday, January 26, 2021FINAL REFUSAL E-MAILED
Tuesday, January 26, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, July 27, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 1, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 19, 2022SOU EXTENSION 1 FILED
Wednesday, January 19, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, January 19, 2022SOU EXTENSION 1 GRANTED
Thursday, January 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 FILED
Wednesday, July 13, 2022SOU EXTENSION 2 GRANTED
Friday, July 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 24, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 24, 2023SOU EXTENSION 3 FILED
Tuesday, January 24, 2023SOU EXTENSION 3 GRANTED
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 13, 2023SOU EXTENSION 4 FILED
Thursday, July 13, 2023SOU EXTENSION 4 GRANTED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Monday, January 22, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU EXTENSION 5 FILED
Monday, January 22, 2024SOU EXTENSION 5 GRANTED
Monday, September 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, January 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED